Formycon

Company snapshot

Who we are Formycon AG is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercializatio

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Formycon. Not investment advice.

• What is Formycon?

  Formycon AG is a pharma organization headquartered in Planegg, DE. Primary therapeutic focus areas include NSCLC. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipe

• Is Formycon publicly traded?

  Formycon appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Formycon develop or market?

  We link 4 drug profile(s) where Formycon is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/formycon-ag#company-drugs.

• What are the latest developments for Formycon?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Formycon focus on?

  Formycon focuses on NSCLC based on our analysis of their pipeline programs and drug development activities.